Caroline Seymour

Managing Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com

Articles

Dr Goel on the Future of an Exosome-Based Liquid Biopsy Plus the Biomarker CA19-9 to Detect Early-Stage Pancreatic Cancer

January 24th 2025

Ajay Goel, PhD, AGAF, discusses upcoming clinical studies examining the prognostic biomarker CA19-9 plus an investigational exosome-based liquid biopsy for the detection of early-stage pancreatic cancer.

Pembrolizumab Plus Lenvatinib and Chemo Misses OS End Point in Gastroesophageal Adenocarcinoma

January 24th 2025

OS was not improved with pembrolizumab plus lenvatinib and chemotherapy vs chemotherapy alone in advanced HER2-negative gastroesophageal adenocarcinoma.

FDA Approves Treosulfan for alloHCT Conditioning in AML and MDS

January 24th 2025

The FDA approved treosulfan plus fludarabine for alloHSCT conditioning in acute myeloid leukemia or myelodysplastic syndrome.

Tislelizumab Plus Chemotherapy Is Active, Tolerable in Advanced Gastric/GEJ Cancer

January 24th 2025

Tislelizumab plus irinotecan, paclitaxel, oxaliplatin, and 5-FU/leucovorin showcased encouraging efficacy and manageable safety in gastric/GEJ cancer.

Maintenance Galinpepimut-S Appears Effective and Safe in AML in Second CR

January 23rd 2025

Galinpepimut-S demonstrated early efficacy signals in patients with acute myeloid leukemia in second complete remission or later.

Tagitanlimab Plus Chemotherapy Receives Chinese Approval for Recurrent/Metastatic Nasopharyngeal Cancer

January 23rd 2025

Tagitanlimab received marketing authorization from the Chinese NMPA for use with cisplatin and gemcitabine for patients with recurrent or metastatic NPC.

Oncology Experts Preview Top Abstracts to be Shared at 2025 ASCO GI

January 22nd 2025

Tanios S. Bekaii-Saab, MD, and Yelena Y. Janjigian, MD, preview top presentations from this year’s Gastrointestinal Cancers Symposium.

Second Cycle of Medicare Drug Price Negotiations Includes 4 Oncologic Agents

January 22nd 2025

The CMS has selected 15 drugs covered under Medicare Part D for the second cycle of the Drug Price Negotiation Program, including enzalutamide, pomalidomide, palbociclib, and acalabrutinib.

Precision Medicine Heats Up Ahead of SOGO Annual Meeting in GI Cancer

January 21st 2025

E. Gabriela Chiorean, MD, FASCO, discusses exciting targeted therapies in the GI space and topics to be discussed at the School of Gastrointestinal Oncology meeting.

ACS Annual Report Shows Cancer Incidence Rates Are Rising in Select Populations

January 21st 2025

The 2025 American Cancer Society Annual Report Showed incidence rates are increasing for many cancer types and disparities remain regarding cancer mortality.

TKIs Look to Solidify a Role Alongside T-DXd in the Second-Line HER2-Mutant NSCLC Setting

January 21st 2025

The second-line setting for HER2-mutated NSCLC is shifting with TKIs looking to demonstrate efficacy and T-DXd under examination in the frontline now.

FDA Grants Orphan Drug Designation to ELC-100 for Pancreatic NETs

January 20th 2025

ELC-100 has been granted orphan drug designation by the FDA for the treatment of patients with pancreatic neuroendocrine tumors.

Pembrolizumab/Radiation/Surgery Improves DFS in Stage III Soft Tissue Sarcoma

January 18th 2025

The addition of pembrolizumab to preoperative radiation therapy followed by surgery prolonged DFS in patients with soft tissue sarcoma of the extremity.

Dr Werutsky on the Effects of HER2-Low Breast Cancer Subtype on Treatment Outcomes

January 17th 2025

Gustavo Werutsky, MD, PhD, discusses an exploratory analysis that outlined associations between HER2-low breast cancer subtype and clinical outcomes.

Dr Parikh on the Clinical Implications of Molecular Testing on mCRC Management

January 17th 2025

Aparna Parikh, MD, discusses the importance of upfront molecular testing in patients with metastatic colorectal cancer.

Preliminary Efficacy, Safety Data Drive Further Exploration of Mezigdomide-Based Combinations in R/R Myeloma

January 17th 2025

David S. Siegel, MD, PhD, discusses early safety and efficacy data that support further development of mezigdomide-based combinations in multiple myeloma.

Early Diagnosis and Treatment Are Critical in Achieving the Best Outcomes in Sarcoma

January 16th 2025

Breelyn Wilky, MD, discusses the importance of disease screening and early diagnosis in the treatment of patients with sarcoma.

Obe-Cel Produces Durable Remissions in Adult R/R B-ALL

January 16th 2025

Obe-cel generated durable remissions in patients with relapsed/refractory B-cell acute lymphoblastic leukemia treated during the FELIX trial.

Zenocutuzumab Addresses High Unmet Need in NRG1-Positive NSCLC and Pancreatic Cancer

January 16th 2025

Alison Schram, MD, details data from the eNRGy study that supported the FDA approval of zenocutuzumab in NRG1 fusion–positive NSCLC and pancreatic adenocarcinoma.

Nivolumab Plus Gemcitabine/Cisplatin Shows Favorable OS/PFS Trend in Asian Unresectable/Metastatic Urothelial Cancer Subpopulation

January 15th 2025

First-line nivolumab plus chemotherapy numerically improved survival vs chemotherapy alone in Asian patients with unresectable/metastatic urothelial cancer.